WO2010120996A1 - Composés de 5,6,7,8-tétrahydropyrido[3,4-d]pyrimidine, leur utilisation comme inhibiteurs de la mtor kinase et de la pi3 kinase, et leurs synthèses - Google Patents

Composés de 5,6,7,8-tétrahydropyrido[3,4-d]pyrimidine, leur utilisation comme inhibiteurs de la mtor kinase et de la pi3 kinase, et leurs synthèses Download PDF

Info

Publication number
WO2010120996A1
WO2010120996A1 PCT/US2010/031188 US2010031188W WO2010120996A1 WO 2010120996 A1 WO2010120996 A1 WO 2010120996A1 US 2010031188 W US2010031188 W US 2010031188W WO 2010120996 A1 WO2010120996 A1 WO 2010120996A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
oxa
alkyl
azabicyclo
oct
Prior art date
Application number
PCT/US2010/031188
Other languages
English (en)
Inventor
Ariamala Gopalsamy
Mengxiao Shi
Arie Zask
Aranapakam Mudumbai Venkatesan
Kevin Joseph Curran
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of WO2010120996A1 publication Critical patent/WO2010120996A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the invention relates to 5,6,7,8-tetrahydropyhdo[3,4-d]pyrimidine compounds and their ring homologues, compositions comprising such a compound, methods of synthesizing such compounds, and methods for treating mTOR-related diseases comprising the administration of an effective amount of such a compound.
  • the invention relates to methods for treating PI3K-related diseases comprising the administration of an effective amount of such a compound.
  • the invention also relates to methods for treating hSMG-1 -related diseases comprising the administration of an effective amount of such a compound.
  • Phosphatidylinositol (hereinafter abbreviated as "Pl") is one of the phospholipids in cell membranes.
  • Pl 4,5 bisphosphate
  • PIP2 Pl (4,5) bisphosphate
  • PI(4,5)P2 or PIP2 is degraded into diacylglycerol and inositol (1 ,4,5) triphosphate by phospholipase C to induce activation of protein kinase C and intracellular calcium mobilization, respectively [M. J. Berhdge et al., Nature, 312, 315 (1984); Y. Nishizuka, Science, 225, 1365 (1984)].
  • PI3K phosphatidylinositol-3 kinase
  • the class Ia PI3K subtype has been most extensively investigated to date. Within the class Ia subtype there are three isoforms ( ⁇ , ⁇ , & ⁇ ) that exist as hetero dimers of a catalytic 1 10-kDa subunit and regulatory subunits of 50-85kDa.
  • the regulatory subunits contain SH2 domains that bind to phosphorylated tyrosine residues within growth factor receptors or adaptor molecules and thereby localize PI3K to the inner cell membrane.
  • PI3K converts PIP2 to PIP3 (phosphatidylinositol-3,4,5- thsphosphate) that serves to localize the downstream effectors PDK1 and Akt to the inner cell membrane where Akt activation occurs.
  • Akt Activated Akt mediates a diverse array of effects including inhibition of apoptosis, cell cycle progression, response to insulin signaling, and cell proliferation.
  • Class Ia PI3K subtypes also contain Ras binding domains (RBD) that allow association with activated Ras providing another mechanism for PI3K membrane localization.
  • RBD Ras binding domains
  • Activated, oncogenic forms of growth factor receptors, Ras, and even PI3K kinase have been shown to aberrantly elevate signaling in the PI3K/Akt/mTOR pathway resulting in cell transformation.
  • PI3K As a central component of the PI3K/Akt/mTOR signaling pathway PI3K (particularly the class Ia ⁇ isoform) has become a major therapeutic target in cancer drug discovery.
  • Class I PI3Ks are Pl, PI(4)P and PI(4,5)P2, with PI(4,5)P2 being the most favored.
  • Class I PI3Ks are further divided into two groups, class Ia and class Ib, because of their activation mechanism and associated regulatory subunits.
  • the class Ib PI3K is p1 10 ⁇ that is activated by interaction with G protein-coupled receptors. Interaction between p1 10 ⁇ and G protein-coupled receptors is mediated by regulatory subunits of 1 10, 87, and 84 kDa.
  • Pl and PI(4)P are the known substrates for class Il PI3Ks; PI(4,5)P2 is not a substrate for the enzymes of this class.
  • Class Il PI3Ks include PI3K C2 ⁇ , C2 ⁇ and C2 ⁇ isoforms, which contain C2 domains at the C terminus, implying that their activity is regulated by calcium ions.
  • the substrate for class III PI3Ks is Pl only. A mechanism for activation of the class III PI3Ks has not been clarified. Because each subtype has its own mechanism for regulating activity, it is likely that activation mechanism(s) depend on stimuli specific to each respective class of PI3K.
  • the compound PM 03 (3-(4-(4-morpholinyl)pyhdo[3',2':4,5]furo[3,2-d]pyrimidin-2- yl)phenol) inhibits PI3K ⁇ and PI3K ⁇ as well as the mTOR enzymes with IC 5 O values of 2, 3, and 50-80 nM respectively.
  • mice of this compound in human tumor xenograft models of cancer demonstrated activity against a number of human tumor models, including the glioblastoma (PTEN null U87MG), prostate (PC3), breast (MDA- MB-468 and MDA-MB-435) colon carcinoma (HCT 1 16); and ovarian carcinoma (SKOV3 and IGROV-1 ); (Raynaud et al, Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases, Cancer Res. 2007 67: 5840-5850).
  • ZSTK474 (2-(2-difluoromethylbenzoimidazol-1 -yl)-4,6- dimorpholino-1 ,3,5-thazine) inhibits PI3K ⁇ and PI3K ⁇ but not the mTOR enzymes with an IC50 values of 16, 4.6 and >10,000 nM respectively (Dexin Kong and Takao Yamori, ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms, Cancer Science, 2007, 98:10 1638-1642).
  • NVP-BEZ-235 (2-methyl-2-(4-(3-methyl-2-oxo-8-(quinolin-3-yl)- 2,3-dihydro-1 H-imidazo[4,5-c]quinolin-1 -yl)phenyl)propanenithle) inhibits both PI3K ⁇ and PI3K ⁇ as well as the mTOR enzymes with IC50 values 4, 5, and "nanomolar".
  • Testing in human tumor xenograft models of cancer demonstrated activity against human tumor models of prostrate (PC-3) and glioblastoma (U-87) cancer. It entered clinical trials in December of 2006 (Verheijen, J. C. and Zask, A., Phosphatidylinositol 3- kinase (PI3K) inhibitors as anticancer drugs, Drugs Fut. 2007, 32(6): 537-547).
  • the compound SF-1 126 (a prodrug form of LY-294002, which is 2-(4- morpholinyl)-8-phenyl-4H-1 -benzopyran-4-one) is "a pan-PI3K inhibitor". It is active in preclinical mouse cancer models of prostrate, breast, ovarian, lung, multiple myeloma, and brain cancers. It began clinical trials in April, 2007 for the solid tumors endometrial, renal cell, breast, hormone refractory prostate and ovarian cancers. (Verheijen, J. C. and Zask, A., Phosphatidylinositol 3-kinase (PI3K) inhibitors as anticancer drugs, Drugs Fut. 2007, 32(6): 537-547).
  • PI3K Phosphatidylinositol 3-kinase
  • Exelixis Inc. (So. San Francisco, CA) recently filed INDs for XL-147 (a selective pan-PI3K inhibitor of unknown structure) and XL-765 (a mixed inhibitor of mTOR and PI3K of unknown structure) as anticancer agents.
  • TargeGen's short-acting mixed inhibitor of PI3K ⁇ and ⁇ , TG-1001 15 is in phase I/I I trials for treatment of infarct following myocardial ischemia-reperfusion injury.
  • Cerylid's antithrombotic PI3K ⁇ inhibitor CBL-1309 (structure unknown) has completed preclinical toxicology studies.
  • lipid kinase inhibitors may parallel protein kinase inhibitors in that nonselective inhibitors may also be brought forward to the clinic.
  • Mammalian Target of Rapamycin is a cell-signaling protein that regulates the response of tumor cells to nutrients and growth factors, as well as controlling tumor blood supply through effects on Vascular Endothelial Growth Factor, VEGF.
  • Inhibitors of mTOR starve cancer cells and shrink tumors by inhibiting the effect of mTOR. All mTOR inhibitors bind to the mTOR kinase. This has at least two important effects. First, mTOR is a downstream mediator of the PI3K/Akt pathway. The PI3K/Akt pathway is thought to be over activated in numerous cancers and may account for the widespread response from various cancers to mTOR inhibitors.
  • mTOR kinase over-activation of the upstream pathway would normally cause mTOR kinase to be over activated as well. However, in the presence of mTOR inhibitors, this process is blocked. The blocking effect prevents mTOR from signaling to downstream pathways that control cell growth. Over-activation of the PI3K/Akt kinase pathway is frequently associated with mutations in the PTEN gene, which is common in many cancers and may help predict what tumors will respond to mTOR inhibitors. The second major effect of mTOR inhibition is anti-angiogenesis, via the lowering of VEGF levels.
  • mTOR inhibitors There are three mTOR inhibitors, which have progressed into clinical trials. These compounds are Wyeth's Torisel, also known as 42-(3-hydroxy-2- (hydroxymethyl)-rapamycin 2-methylpropanoate, CCI-779 or Temsirolimus; Novartis' Everolimus, also known as 42-0-(2-hydroxyethyl)-rapamycin, or RAD 001 ; and Ariad's AP23573 also known as 42-(dimethylphopsinoyl)-rapamycin.
  • the FDA has approved Torisel for the treatment of advanced renal cell carcinoma.
  • Torisel is active in a NOS/SCID xenograft mouse model of acute lymphoblastic leukemia [Teachey et al, Blood, 107(3), 1 149-1 155, 2006].
  • FDA U. S. Food and Drug Administration
  • Everolimus AFINITORTM
  • AP23573 has been given orphan drug and fast- track status by the FDA for treatment of soft-tissue and bone sarcomas.
  • the three mTOR inhibitors have non-linear, although reproducible pharmacokinetic profiles. Mean area under the curve (AUC) values for these drugs increase at a less than dose related way.
  • the three compounds are all semi-synthetic derivatives of the natural macrolide antibiotic rapamycin. It would be desirable to find fully synthetic compounds, which inhibit mTOR that are more potent and exhibit improved pharmacokinetic behaviors.
  • Yamashita (Genes Dev. 2001 15: 2215-2228) characterized two isoforms of hSMG-1 proteins, p430 and p400, which are expressed in various cell lines of human, monkey, rat, and mouse. Yamashita's p400 hSMG-1 isoform is a 3529-amino-acid protein of 396,040 Daltons.
  • Brumbaugh (Molecular Cell, Volume 14, Issue 5, 4 June 2004, Pages 585-598) isolated a 3521 amino acid polypeptide with a deduced molecular mass of 395 kDa.
  • Brumbaugh's hSMG-1 is eight amino acids shorter at the amino terminus than the protein isolated by Yamashita.
  • Both hllpfl and p53 are physiological targets for hSMG-1 in intact cells. Rapamycin in the presence of purified recombinant FKBP12 does not inhibit the kinase activity of hSMG-1. Wortmannin, the modified steroidal anti-infective agent, and the purine caffeine inhibit the kinase activity of hSMG-1 with IC50 values of -60 nM and 0.3 mM, respectively. However, these are non-specific protein kinase inhibitors.
  • hSMG-1 Specific inhibition of hSMG-1 is a potential therapeutic strategy because inhibitors of hSMG-1 cause the accumulation of truncated p53 proteins from a premature translation termination codon (PTC) allele, as well as the increase in the level of mRNA with PTC, opening the possibility of the above strategy by specifically suppressing nonsense-mediated mRNA decay (NMD) through the inhibition of hSMG-1.
  • PTC premature translation termination codon
  • NMD nucleic acid deficiency virus
  • the specific inhibition of NMD may provide a novel therapeutic strategy based on the type of mutation rather than on the gene in which the mutation resides.
  • the inhibitors of SMG-1 can rescue the synthesis of mature proteins through two independent mechanisms (i.e., the inhibition of NMD to increase the mRNA level and the suppression of translational termination that leads to the synthesis of a read-through mature protein product). In this sense, the specific inhibitors of hSMG-1 will be of potential therapeutic importance for all the genetic diseases associated with PTC mutations.
  • PI3K inhibitors, mTOR inhibitors, and hSMG-1 inhibitors are expected to be novel types of medicaments useful against cell proliferation disorders, especially as carcinostatic agents.
  • the instant invention is directed to these and other important ends.
  • the invention provides compounds of the Formula I:
  • the invention provides compositions comprising a compound of the invention, and methods for making compounds of the invention.
  • the invention provides methods for inhibiting PI3K, mTOR and hSMG-1 in a subject, and methods for treating PI3K-related, mTOR-related and hSMG-1 -related disorders in a mammal in need thereof.
  • the invention provides compounds of the Formula I:
  • R 1 is independently C-i-C ⁇ alkyl-, C 6 -C- ⁇ 4 aryl-, d-Cgheteroaryl-, halogen, or hydroxyl;
  • p is 0, 1 , 2, 3, or 4;
  • het is a d-Cgheterocyclyl- group containing at least one oxygen atom;
  • m is 0 or 1 ;
  • Ar is C 6 -C- ⁇ 4 aryl- or C r C 9 heteroaryl- wherein the C 6 -C- ⁇ 4 aryl- or d-Cgheteroaryl- is optionally substituted with from 1 to 4 substituents independently selected from d- C 6 alkyl-, halogen, haloalkyl-, hydroxyl, hydroxyl(C r C 6 alkyl)-, H 2 N-, aminoalkyl-, di(d- C6alkyl)amino-, HO 2 C-, (d-C ⁇ alkoxyJcarbonyl-, (d-Cealky ⁇ carboxyl-, di(d- C 6 alkyl)amido-, H 2 NC(O)-, (Ci-C 6 alkyl)amido-, and O 2 N-;
  • R 2 is H or CrC 6 alkyl-;
  • R 3 is R 6 , R 7 R 8 N-, R 9 S-, or R 9 O-
  • R 6 is H; CrC ⁇ alkyl- optionally substituted with from 1 to 3 substituents independently selected from d-C ⁇ alkoxy-, H 2 N-, (Ci-C6alkyl)amino-, di(d- C 6 alkyl)amino-, C 6 -Ci 4 aryl-, d-Cgheterocyclyl- optionally substituted by C r C 6 alkyl-, and d-Cgheteroaryl-; Ci-C6alkoxy-; Ci-Cgheteroaryl- optionally substituted with from 1 to 3 substituents independently selected from Ci-C6alkyl- optionally substituted with H 2 N-, (Ci-C 6 alkyl)amino-, or di(d-C 6 alkyl)amino-, heterocyclyl(d-C 6 alkyl)-, halogen, hydroxyl, H 2 N-, O 2 N-, H 2 NSO 2 -, HO 2 C-,
  • R 10 and R 11 are each independently H, CrC ⁇ alkyl-, Ci-C6alkoxy(C 2 -C6alkylene)-, (Ci-C6alkyl)amino-C 2 -C6alkylene-, di(Ci-C6alkyl)amino-C 2 -C6alkylene-, C 2 -C6alkenyl, C 2 -C 6 alkynyl, C 6 -Ci 4 aryl-, (C 6 -Ci 4 aryl)alkyl-, drCscycloalkyl-, Ci-Cgheteroaryl-, (d- Cgheteroaryl)alkyl-, Ci-Cgheterocyclyl-, or heterocyclyl(Ci-C 6 alkyl-); or R 10 and R 11 , when taken together with the nitrogen to which they are attached, form a 3- to 7- membered heterocycle wherein up to two of the carbon atoms of the hetero
  • R 7 and R 8 are each independently H; CrC ⁇ alkyl- optionally substituted with from 1 to 3 substituents independently selected from Ci-C ⁇ alkoxy-, H 2 N-, (Ci-C6alkyl)amino-, di(Ci-C 6 alkyl)amino-, halogen, C 6 -d 4 aryl-, Ci-Cgheterocyclyl- optionally substituted by Ci-C 6 alkyl-, and Ci-Cgheteroaryl-; Ci-C 6 alkoxy-; Ci-Cgheteroaryl- optionally substituted with from 1 to 3 substituents independently selected from CrC ⁇ alkyl- optionally substituted with H 2 N-, (d-C 6 alkyl)amino-, or di(d-C 6 alkyl)amino-, heterocyclyl(Ci- C ⁇ alkyl)- optionally substituted with d-C ⁇ alkyl, halogen, hydroxyl, H 2 N-,
  • R 9 is Ci-C ⁇ alkyl-, C 6 -C- ⁇ 4 aryl-, (C 6 -C- ⁇ 4 aryl)alkyl- optionally substituted by H 2 N-, C-i-Cgheterocyclyl-, C 3 -C 8 CyClOaIkVl-, CrC ⁇ hydroxylalkyl-, or C-i-Ceperfluoroalkyl-; n is O, 1 , or 2; R 4 is: a) hydrogen; b) C-i-Csacyl-, optionally substituted with from 1 to 3 substituents independently selected from: i) C-i-C ⁇ alkoxy-, ⁇ ) (Ci-C 6 )alkyl-, iii) (Ci-C6alkyl)amino-, iv) C 3 -C 8 CVClOaIkVl-, v) di(Ci-C 6 alkyl)amino-, vi)
  • I- optionally substituted with frx Om i) C- ⁇ -C 6 alkoxy-, ⁇ ) (Ci-C 6 alkoxy)carbonyl-, iii) (Ci-C6alkyl)amino-, iv) di(Ci-C6alkyl)amino-, v) C 3 -C 8 cycloalkyl-, vi) halogen, vii) HC(O)-, viii) HO 2 C-, ix) and H 2 N-; d) C-i-Ceaminoalkyl- optionally substituted with a substituent selected from: i) C 6 -Ci 4 aryl- optionally substituted with halogen, ii) (Ci-Cgheteroaryl)alkyl-, iii) (C 6 -Ci 4 aryl)alkyl-, iv) H 2 N-Ci-C 6 alkylene-, v) (Ci-C
  • R 12 and R 13 are each independently: a) H; b) C1 -C6alkyl- optionally substituted with a substituent selected from: i) CrC 6 alkylC(O)NH-, ii) H 2 N-, iii) (Ci-C6alkyl)amino-, iv) and di(Ci-C 6 alkyl)amino-, c) C 2 -C 6 alkenyl- d) Cs-Cscycloalkyl-; e) C6-C- ⁇ 4 aryl- optionally substituted with a substituent selected from: i) halogen, ii) and d-Cgheterocycle wherein the d-Cgheterocycle is optionally substituted with (C r C 6 alkoxy)carbonyl-; f) d-Cgheteroaryl-; g) (d-Cgheteroaryl)alkyl-; h) heterocycly
  • Ci-C 6 alkyl-, C 6 -Ci 4 aryl-, (C 6 -d 4 aryl)alkyl-, d-Cgheterocyclyl-, or drCscycloalkyl- is optionally substituted with a Ci-C 6 alkoxy-, Ci-C 6 alkyl-, C 3 -C 8 cycloalkyl-, NC-, or halogen;
  • R 5 are independently H or d-C ⁇ alkyl.
  • the invention provides compounds of the Formula II:
  • the invention provides compounds of the Formula III:
  • the invention provides compounds of the Formula IV:
  • the invention provides compounds of the Formula V:
  • the invention provides compounds of the Formula Vl:
  • the invention provides compounds of the Formula VII:
  • the invention provides compounds of the Formula VIII:
  • the invention provides compounds of the Formula IX:
  • R 2 is H.
  • R 3 is R 7 R 8 N-.
  • R 7 is C-i-Cgheteroaryk
  • R 7 is pyridyl. In one embodiment, R 7 is 3- or 4-pyridyl.
  • R 8 is H.
  • R 4 is R 14 S(O) 2 -.
  • R 14 is Ci-C ⁇ alkyl-.
  • R 14 is CH 3 -.
  • Illustrative compounds of the present Formula III are set forth below:
  • Illustrative compounds of the present Formula V are set forth below: i ⁇ - ⁇ S-oxa- ⁇ -azabicycloP ⁇ .iloct- ⁇ -yO-S ⁇ J ⁇ -tetrahydropyhdoP ⁇ -dlpyhmidin ⁇ - yl]phenyl ⁇ -3-pyhdin-3-ylurea;
  • Illustrative compounds of the present Formula VIII are set forth below: i ⁇ - ⁇ -oxa-a-azabicyclop ⁇ .iloct-a-ylJ- ⁇ J-dihydro- ⁇ H-pyrroloP ⁇ -dlpyrimidin ⁇ - yl]phenyl ⁇ -3-pyhdin-3-ylurea; 1-methyl-3- ⁇ 4-[4-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-6,7-dihydro-5H-pyrrolo[3,4- d]pyhmidin-2-yl]phenyl ⁇ urea;
  • Illustrative compounds of the present Formula IX are set forth below: i ⁇ - ⁇ a-oxa- ⁇ -azabicyclop ⁇ .iloct- ⁇ -ylJ- ⁇ J-dihydro- ⁇ H-pyrroloP ⁇ -dlpyrimidin ⁇ - yl]phenyl ⁇ -3-pyhdin-3-ylurea;
  • the invention provides pharmaceutical compositions comprising compounds or pharmaceutically acceptable salts of the compounds of the present Formula I and a pharmaceutically acceptable carrier.
  • the invention provides a pharmaceutically acceptable carrier suitable for oral administration and the composition comprises an oral dosage form.
  • the invention provides a composition comprising a compound of
  • Formula I a second compound selected from the group consisting of a topoisomerase I inhibitor, procarbazine, dacarbazine, gemcitabine, capecitabine, methotrexate, taxol, taxotere, mercaptopuhne, thioguanine, hydroxyurea, cytarabine, cyclophosphamide, ifosfamide, nitrosoureas, cisplatin, carboplatin, mitomycin, dacarbazine, procarbizine, etoposide, teniposide, campathecins, bleomycin, doxorubicin, idarubicin, daunorubicin, dactinomycin, plicamycin, mitoxantrone, L-asparaginase, doxorubicin, epirubicin, 5-fluorouracil, docetaxel, paclitaxel, leucovohn, levamisole,mitotecan
  • the second compound is Avastin.
  • the invention provides a method of treating a PI3K-related disorder, comprising administering to a mammal in need thereof a compound of Formula I in an amount effective to treat a PI3K-related disorder.
  • the PI3K-related disorder is selected from restenosis, atherosclerosis, bone disorders, arthritis, diabetic retinopathy, psoriasis, benign prostatic hypertrophy, atherosclerosis, inflammation, angiogenesis, immunological disorders, pancreatitis, kidney disease, and cancer.
  • the PI3K-related disorder is cancer.
  • the cancer is selected from the group consisting of leukemia, skin cancer, bladder cancer, breast cancer, uterus cancer, ovary cancer, prostate cancer, lung cancer, colon cancer, pancreas cancer, renal cancer, gastric cancer, and brain cancer.
  • the invention provides a method of treating an mTOR-related disorder, comprising administering to a mammal in need thereof a compound of Formula I in an amount effective to treat an mTOR-related disorder.
  • the mTOR-related disorder is selected from restenosis, atherosclerosis, bone disorders, arthritis, diabetic retinopathy, psoriasis, benign prostatic hypertrophy, atherosclerosis, inflammation, angiogenesis, immunological disorders, pancreatitis, kidney disease, and cancer.
  • the mTOR-related disorder is cancer.
  • the cancer is selected from the group consisting of leukemia, skin cancer, bladder cancer, breast cancer, uterus cancer, ovary cancer, prostate cancer, lung cancer, colon cancer, pancreas cancer, renal cancer, gastric cancer, and brain cancer.
  • the invention provides a method of treating an hSMG-1 -related disorder, comprising administering to a mammal in need thereof a compound of Formula I in an amount effective to treat an hSMG-1 -related disorder.
  • the hSMG-1 -related disorder is selected from restenosis, atherosclerosis, bone disorders, arthritis, diabetic retinopathy, psoriasis, benign prostatic hypertrophy, atherosclerosis, inflammation, angiogenesis, immunological disorders, pancreatitis, kidney disease, and cancer.
  • the hSMG-1 -related disorder is cancer.
  • the cancer is selected from the group consisting of leukemia, skin cancer, bladder cancer, breast cancer, uterus cancer, ovary cancer, prostate cancer, lung cancer, colon cancer, pancreas cancer, renal cancer, gastric cancer, and brain cancer.
  • the invention provides a method of treating advanced renal cell carcinoma, comprising administering to a mammal in need thereof the compounds or a pharmaceutically acceptable salt of the compounds of the present Formula I in an amount effective to treat advanced renal cell carcinoma.
  • the invention provides a method of treating acute lymphoblastic leukemia, comprising administering to a mammal in need thereof the compounds or a pharmaceutically acceptable salt of the compounds of any of the present Formula I in an amount effective to treat acute lymphoblastic leukemia.
  • the invention provides a method of treating acute malignant melanoma, comprising administering to a mammal in need thereof the compounds or a pharmaceutically acceptable salt of the compounds of any of the present Formula I in an amount effective to treat malignant melanoma.
  • the invention provides a method of treating soft-tissue or bone sarcoma, comprising administering to a mammal in need thereof the compounds or a pharmaceutically acceptable salt of the compounds of any of the present formula I in an amount effective to treat soft-tissue or bone sarcoma.
  • the invention provides a method of treating a cancer selected from the group consisting of leukemia, skin cancer, bladder cancer, breast cancer, uterus cancer, ovary cancer, prostate cancer, lung cancer, colon cancer, pancreas cancer, renal cancer, gastric cancer, and brain cancer comprising administering to a mammal in need thereof a composition comprising a compound of Formula I; a second compound selected from the group consisting of a topoisomerase I inhibitor, procarbazine, dacarbazine, gemcitabine, capecitabine, methotrexate, taxol, taxotere, mercaptopuhne, thioguanine, hydroxyurea, cytarabine, cyclophosphamide, ifosfamide, nitrosoureas, cisplatin, carboplatin, mitomycin, dacarbazine, procarbizine, etoposide, teniposide, campathecins, bleomycin,
  • the invention provides a method of inhibiting mTOR in a subject, comprising administering to a subject in need thereof a compound of Formula I in an amount effective to inhibit mTOR.
  • the invention provides a method of inhibiting PI3K in a subject, comprising administering to a subject in need thereof a compound of Formula I in an amount effective to inhibit PI3K.
  • the invention provides a method of inhibiting hSMG-1 in a subject, comprising administering to a subject in need thereof a compound of Formula I in an amount effective to inhibit hSMG-1 .
  • the invention provides a method of inhibiting mTOR, PI3K, and hSMG-1 together in a subject, comprising administering to a subject in need thereof a compound of Formula I in an amount effective to inhibit mTOR, PI3K, and hSMG-1 .
  • the invention provides a method of synthesizing a compound of
  • the invention provides a method of synthesizing a compound of Formula I further comprising: a) when NHR 2 is present, reacting compound 16 with an acylating agent R 3 C(O)X, wherein R 3 is as defined for Formula I to give 17:
  • compositions include but are not limited to, e.g., water-soluble and water-insoluble salts, such as the acetate, aluminum, amsonate
  • Some compounds within the present invention possess one or more chiral centers, and the present invention includes each separate enantiomer of such compounds as well as mixtures of the enantiomers. Where multiple chiral centers exist in compounds of the present invention, the invention includes each combination as well as mixtures thereof. All chiral, diastereomehc, and racemic forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials.
  • An "effective amount" when used in connection a compound of the present invention of this invention is an amount effective for inhibiting mTOR or PI3K in a subject.
  • the number of carbon atoms present in a given group is designated "C x -Cy", where x and y are the lower and upper limits, respectively.
  • a group designated as “CrC ⁇ ” contains from 1 to 6 carbon atoms.
  • the carbon number as used in the definitions herein refers to carbon backbone and carbon branching, but does not include carbon atoms of the substituents, such as alkoxy substitutions and the like.
  • Acyl- refers to a group having a straight, branched, or cyclic configuration or a combination thereof, attached to the parent structure through a carbonyl functionality. Such groups may be saturated or unsaturated, aliphatic or aromatic, and carbocyclic or heterocyclic. Examples of a d-Csacyl- group include acetyl-, benzoyl-, nicotinoyl-, propionyl-, isobutyryl-, oxalyl-, and the like. Lower-acyl refers to acyl groups containing one to four carbons.
  • An acyl group can be unsubstituted or substituted with one or more of the following groups: halogen, H 2 N-, (C r C 6 alkyl)amino-, di(C r C 6 alkyl)amino-, (CrC 6 alkyl)C(O)N(Ci-C 3 alkyl)-, (C r C 6 alkyl)carboxyamido-, HC(O)NH-, H 2 NC(O)-, (C r C 6 alkyl)NHC(O)-, di(C r C 6 alkyl)NC(O)-, -CN, hydroxyl, C r C 6 alkoxy-, C r C 6 alkyl-, HO 2 C- , (C-i-CealkoxyJcarbonyl-, (CrC 6 alkyl)C(O)-, C 6 -Ci 4 aryl-, C r C 9 heteroaryl-, or C 3 - Cs
  • Alkenyl- refer to a straight or branched chain unsaturated hydrocarbon containing at least one double bond.
  • Examples of a C 2 -Cioalkenyl- group include, but are not limited to, ethylene, propylene, 1-butylene, 2-butylene, isobutylene, sec- butylene, 1-pentene, 2-pentene, isopentene, 1 -hexene, 2-hexene, 3-hexene, isohexene, 1-heptene, 2-heptene, 3-heptene, 1-octene, 2-octene, 3-octene, 4-octene, 1-nonene, 2- nonene, 3-nonene, 4-nonene, 1 -decene, 2-decene, 3-decene, 4-decene and 5-decene.
  • An alkenyl- group can be unsubstituted or substituted with one or more of the following groups: halogen, H 2 N-, (C r C 6 alkyl)amino-, di(C r C 6 alkyl)amino-, (Ci-C 6 alkyl)C(O)N(C r C 3 alkyl)-, (C r C 6 alkyl)carboxyamido-, HC(O)NH-, H 2 NC(O)-, (C r C 6 alkyl)NHC(O)-, di(C r C 6 alkyl)NC(O)-, NC-, hydroxyl, C r C 6 alkoxy-, C r C 6 alkyl-, HO 2 C-, (C r C6alkoxy)carbonyl-, (Ci-C6alkyl)C(O)-, C6-Ci 4 aryl-, d-Cgheteroaryl-, and C 3 -
  • Alkoxy- refers to the group R-O- where R is an alkyl group, as defined below.
  • Exemplary C-i-C ⁇ alkoxy- groups include but are not limited to methoxy, ethoxy, n- propoxy, 1-propoxy, n-butoxy and t-butoxy.
  • An alkoxy group can be unsubstituted or substituted with one or more of the following groups: halogen, hydroxyl, C-i-C ⁇ alkoxy-, H 2 N-, (Ci-C 6 alkyl)amino-, di(C r C 6 alkyl)amino-, (C r C 6 alkyl)C(O)N(Ci-C 3 alkyl)-, (C r C 6 alkyl)carboxyamido-, HC(O)NH-, H 2 NC(O)-, (C r C 6 alkyl)NHC(O)-, di(C r C 6 alkyl)NC(O)-, NC-, C r C 6 alkoxy-, HO 2 C-, (Ci-Cealkoxyjcarbonyl-, (C r C 6 alkyl)C(O)-, C 6 -Ci 4 aryl-, d-Cgheteroaryl-, Cs-Cs
  • (Alkoxy)carbonyl- refers to the group alkyl-O-C(O)-.
  • Exemplary (Cr C6alkoxy)carbonyl- groups include but are not limited to methoxy, ethoxy, n-propoxy, 1- propoxy, n-butoxy and t-butoxy.
  • An (alkoxy)carbonyl group can be unsubstituted or substituted with one or more of the following groups: halogen, hydroxyl, H 2 N-, (Cr C 6 alkyl)amino-, di(C r C 6 alkyl)amino-, (C r C 6 alkyl)C(O)N(Ci-C 3 alkyl)-, (C r C 6 alkyl)carboxyamido-, HC(O)NH-, H 2 NC(O)-, (Ci-C 6 alkyl)NHC(O)-, di(Ci- C 6 alkyl)NC(O)-, NC-, C r C 6 alkoxy-, HO 2 C-, (C r C 6 alkoxy)carbonyl-, (C r C 6 alkyl)C(O)-, C 6 -Ci 4 aryl-, d-Cgheteroaryl-, Cs-Cscycloalkyl-,
  • Alkyl- refers to a hydrocarbon chain that may be a straight chain or branched chain, containing the indicated number of carbon atoms, for example, a Ci-Cioalkyl- group may have from 1 to 10 (inclusive) carbon atoms in it. In the absence of any numerical designation, “alkyl” is a chain (straight or branched) having 1 to 6 (inclusive) carbon atoms in it.
  • CrC ⁇ alkyl- groups include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, neopentyl, and isohexyl.
  • An alkyl- group can be unsubstituted or substituted with one or more of the following groups: halogen, H 2 N-, (CrC6alkyl)amino-, di(d- C 6 alkyl)amino-, (CrC 6 alkyl)C(O)N(CrC 3 alkyl)-, (C r C 6 alkyl)carboxyamido-, HC(O)NH-, H 2 NC(O)-, (CrC 6 alkyl)NHC(O)-, di(CrC 6 alkyl)NC(O)-, NC-, hydroxyl, Ci-C 6 alkoxy-, d- C 6 alkyl-, HO 2 C-, (Ci-C 6 alkoxy)carbonyl-, (C r C 6 alkyl)C(O)-, C 6 -d 4 aryl-, C r Cgheteroaryl-, C 3 -C 8 CyClOaIk
  • (Alkyl)amino- refers to an -NH group, the nitrogen atom of said group being attached to an alkyl group, as defined above.
  • Representative examples of an (Cr C6alkyl)amino- group include, but are not limited to CH 3 NH-, CH 3 CH 2 NH-, CH 3 CH 2 CH 2 NH-, CH 3 CH 2 CH 2 CH 2 NH-, (CH 3 ) 2 CHNH-, (CHs) 2 CHCH 2 NH-,
  • An (alkyl)amino group can be unsubstituted or substituted with one or more of the following groups: halogen, H 2 N-, (Ci-C6alkyl)amino-, di(Ci-C 6 alkyl)amino-, (CrC 6 alkyl)C(O)N(C r C 3 alkyl)-, (d-CealkyOcarboxyamido-, HC(O)NH-, H 2 NC(O)-, (C r C 6 alkyl)NHC(O)-, di(d-C 6 alkyl)NC(O)-, NC-, hydroxyl, d- C 6 alkoxy-, C r C 6 alkyl-, HO 2 C-, (d-CealkoxyJcarbonyl-, (Ci-C 6 alkyl)C(O)-, C 6 -d 4 ary
  • Alkylcarboxyl- refers to an alkyl group, defined above, and attached to the parent structure through the oxygen atom of a carboxyl (C(O)-O-) functionality.
  • Examples of (d-Cealky ⁇ carboxyl- include acetoxy, propionoxy, propylcarboxyl, and isopentylcarboxyl.
  • alkylene- refers to alkyl-, alkenyl-, and alkynyl- groups, as defined above, having two points of attachment within a chemical structure.
  • Examples of -C-i-C ⁇ alkylene- include ethylene (-CH 2 CH 2 -), propylene (- CH 2 CH 2 CH 2 -), and dimethylpropylene (-CH 2 C(CHs) 2 CH 2 -).
  • alkynylene- examples include ethynylene (-C ⁇ C-) and propynylene (-C ⁇ C — CH 2 -).
  • Alkynyl- refers to a straight or branched chain unsaturated hydrocarbon containing at least one triple bond.
  • Examples of a C 2 -Cioalkynyl- group include, but are not limited to, acetylene, propyne, 1-butyne, 2-butyne, isobutyne, sec-butyne, 1- pentyne, 2-pentyne, isopentyne, 1-hexyne, 2-hexyne, 3-hexyne, isohexyne, 1-heptyne, 2-heptyne, 3-heptyne, 1-octyne, 2-octyne, 3-octyne, 4-octyne, 1-nonyne, 2-nonyne, 3- nonyne, 4-nonyne, 1-decyne, 2-decyne, 3-decyne, 4-decyne and 5-decyne.
  • An alkynyl group can be unsubstituted or substituted with one or more of the following groups: halogen, H 2 N-, (C r C 6 alkyl)amino-, di(C r C 6 alkyl)amino-, (Ci-C 6 alkyl)C(O)N(CrC 3 alkyl)- , (d-CealkyOcarboxyamido-, HC(O)NH-, H 2 NC(O)-, (Ci-C 6 alkyl)NHC(O)-, di(Ci- C 6 alkyl)NC(O)-, NC-, hydroxyl, C r C 6 alkoxy-, C r C 6 alkyl-, HO 2 C-, (C r C 6 alkoxy)carbonyl-, (CrC 6 alkyl)C(O)-, C 6 -C- ⁇ 4 aryl-, C r C 9 heteroaryl-, and C 3 - Cscycl
  • Amine-protecting group refers to a radical when attached to a nitrogen atom in a target molecule is capable of surviving subsequent chemical reactions applied to the target molecule i.e. hydrogenation, reaction with acylating agents, alkylation etc. The amine-protecting group can later be removed.
  • Amine protecting groups include, but are not limited to, fluorenylmethoxycarbonyl (FMOC), tert-butoxycarbonyl (t-BOC), benzyloxycarbonyl (Z), those of the acyl type (e.g., formyl, benzoyl, thfluoroacetyl, p- tosyl, aryl- and alkylphosphoryl, phenyl- and benzylsulfonyl, o-nitrophenylsulfenyl, o- nitrophenoxyacetyl), and of the urethane type (e.g.
  • acyl type e.g., formyl, benzoyl, thfluoroacetyl, p- tosyl, aryl- and alkylphosphoryl, phenyl- and benzylsulfonyl, o-nitrophenylsulfenyl, o- nitrophenoxyacetyl
  • Amine-protecting groups are made using a reactive agent capable of transferring an amine-protecting group to a nitrogen atom in the target molecule.
  • an amine-protecting agent examples include, but are not limited to, C-i-C ⁇ aliphatic acid chlorides or anhydrides, C 6 -Ci 4 arylcarboxylic acid chlorides or anhydrides, t- butylchloroformate, di-tert-butyl dicarbonate, butoxycarbonyloxyimino-2- phenylacetonitrile, t-butoxycarbonyl azide, t-butylfluoroformate, fluorenylmethoxycarbonyl chloride, fluorenylmethoxycarbonyl azide, fluorenylmethoxycarbonyl benzotriazol-1-yl, ( ⁇ -fluorenylmethoxycarbonyOsuccinimidyl carbonate, fluorenylmethoxycarbonyl pentafluorophexoxide, trichloroacetyl chloride, methyl-, ethyl-, trichloromethyl- chloroformate, and other
  • Aryl- refers to an aromatic hydrocarbon group.
  • Examples of an C 6 -C- ⁇ 4 aryl- group include, but are not limited to, phenyl, 1-naphthyl, 2-naphthyl, 3-biphen-1-yl, anthryl, tetrahydronaphthyl, fluorenyl, indanyl, biphenylenyl, and acenaphthenyl.
  • An aryl group can be unsubstituted or substituted with one or more of the following groups: d- C ⁇ alkyl-, halogen, haloalkyl-, hydroxyl, hydroxyl(CrC 6 alkyl)-, H 2 N-, aminoalkyl-, di(d- C 6 alkyl)amino-, HO 2 C-, (C r C 6 alkoxy)carbonyl-, (C r C 6 alkyl)carboxyl-, di(d- C 6 alkyl)amido-, H 2 NC(O)-, (C r C 6 alkyl)amido-, or O 2 N-.
  • (Aryl)alkyl- refers to an alkyl group, as defined above, wherein one or more of the alkyl group's hydrogen atoms have been replaced with an aryl group as defined above.
  • (C 6 -Ci 4 Aryl)alkyl- moieties include benzyl, benzhydryl, 1-phenylethyl, 2- phenylethyl, 3-phenylpropyl, 2-phenylpropyl, 1 -naphthylmethyl, 2-naphthylmethyl and the like.
  • An (aryl)alkyl group can be unsubstituted or substituted with one or more of the following groups: halogen, H 2 N-, hydroxyl, (C r C 6 alkyl)amino-, di(CrC 6 alkyl)amino-, (CrC 6 alkyl)C(O)N(Ci-C 3 alkyl)-, (Ci-C 6 alkyl)carboxyamido-, HC(O)NH-, H 2 NC(O)-, (C r C 6 alkyl)NHC(O)-, di(C r C 6 alkyl)NC(O)-, NC-, hydroxyl, C r C 6 alkoxy-, C r C 6 alkyl-, HO 2 C- , (CrC 6 alkoxy)carbonyl-, (CrC 6 alkyl)C(O)-, C 6 -Ci 4 aryl-, C r C 9 heteroaryl-, C 3
  • Carboxyamidoalkyl- refers to a primary carboxyamide (CONH 2 ), a secondary carboxyamide (CONHR') or a tertiary carboxyamide (CONR 1 R"), where R' and R" are the same or different substituent groups selected from CrC ⁇ alkyl-, C 2 -C 6 alkenyl, C 2 - C 6 alkynyl, C 6 -Ci 4 aryl-, C r C 9 heteroaryl-, or C 3 -C 8 CyClOaIkVl-, attached to the parent compound by an -C-i-C ⁇ alkylene- group as defined above.
  • Cs-Cscycloalkyl- refers to a monocyclic, non-aromatic, saturated hydrocarbon ring.
  • Representative examples of a Cs-Cscycloalkyl- include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • a cycloalkyl can be unsubstituted or independently substituted with one or more of the following groups: halogen, H 2 N-, (Ci-C 6 alkyl)amino-, di(C r C 6 alkyl)amino-, (d- C 6 alkyl)C(O)N(C r C 3 alkyl)-, (C r C 6 alkyl)carboxyamido-, HC(O)NH-, H 2 NC(O)-, (C r C 6 alkyl)NHC(O)-, di(C r C 6 alkyl)NC(O)-, NC-, hydroxyl, C r C 6 alkoxy-, C r C 6 alkyl-, HO 2 C- , (Ci-C 6 alkoxy)carbonyl-, (CrC 6 alkyl)C(O)-, C 6 -Ci 4 aryl-, C r C 9 heteroaryl-, or C 3 - C
  • Di(alkyl)amino- refers to a nitrogen atom attached to two alkyl groups, as defined above. Each alkyl group can be independently selected. Representative examples of an di(Ci-C6alkyl)amino- group include, but are not limited to, -N(CH 3 ) 2 , - N(CH 2 CH 3 )(CH 3 ), -N(CH 2 CH 3 ) 2 , -N(CH 2 CH 2 CH 3 ) 2 , -N(CH2CH 2 CH 2 CH 3 )2,
  • the two alkyl groups on the nitrogen atom when taken together with the nitrogen to which they are attached, can form a 3- to 7- membered nitrogen containing heterocycle wherein up to two of the carbon atoms of the heterocycle can be replaced with -N(H)-, -N(CrC 6 alkyl)-, -N(C 3 - Cscycloalkyl)-, -N(C 6 -Ci 4 aryl)-, -N(Ci-C 9 heteroaryl)-, -N(Ci-C 6 aminoalkyl)-, -N(C 6 - C- ⁇ 4 arylamino)-, -0-, -S-, -S(O)-, Or -S(O) 2 -.
  • Halo or halogen refers to fluorine, chlorine, bromine, or iodine.
  • Heteroaryl- refers to 5-10-membered mono and bicyclic aromatic groups containing at least one heteroatom selected from oxygen, sulfur and nitrogen.
  • monocyclic d-Cgheteroaryl- radicals include, but are not limited to, oxazinyl, thiazinyl, diazinyl, triazinyl, thiadiazoyl, tetrazinyl, imidazolyl, tetrazolyl, isoxazolyl, furanyl, furazanyl, oxazolyl, thiazolyl, thiophenyl, pyrazolyl, triazolyl, pyrimidinyl, N-pyridyl, 2-pyridyl, 3-pyridyl and 4-pyridyl.
  • bicyclic C r Cgheteroaryl- radicals include but are not limited to, benzimidazolyl, indolyl, isoquinolinyl, benzofuranyl, benzothiophenyl, indazolyl, quinolinyl, quinazolinyl, purinyl, benzisoxazolyl, benzoxazolyl, benzthiazolyl, benzodiazolyl, benzotriazolyl, isoindolyl, and indazolyl.
  • the contemplated heteroaryl- rings or ring systems have a minimum of 5 members.
  • dheteroaryl- radicals would include but are not limited to tetrazolyl
  • C 2 heteroaryl- radicals include but are not limited to triazolyl, thiadiazoyl, and tetrazinyl
  • Cgheteroaryl- radicals include but are not limited to quinolinyl and isoquinolinyl.
  • a heteroaryl group can be unsubstituted or substituted with one or more of the following groups: CrC ⁇ alkyl-, halogen, d-C ⁇ haloalkyl-, hydroxyl, d- Cehydroxylalkyl-, H 2 N-, C r C 6 aminoalkyl-, di(C r C 6 alkyl)amino-, -COOH, (C r C 6 alkoxy)carbonyl-, (CrC 6 alkyl)carboxyl-, di(Ci-C 6 alkyl)amido-, H 2 NC(O)-, (d- C 6 alkyl)amido-, or O 2 N-.
  • (Heteroaryl)alkyl- refers to an alkyl group, as defined above, wherein one or more of the alkyl group's hydrogen atoms have been replaced with a heteroaryl- group as defined above.
  • Examples of (d-CgheteroaryOalkyl- moieties include 2-pyhdylmethyl, 2-thiophenylethyl, 3-pyhdylpropyl, 2-quinolinylmethyl, 2-indolylmethyl, and the like.
  • a (heteroaryl)alkyl group can be unsubstituted or substituted with one or more of the following groups: halogen, H 2 N-, hydroxyl, (Ci-C6alkyl)amino-, di(Ci-C6alkyl)amino-, (Ci-C 6 alkyl)C(O)N(Ci-C 3 alkyl)-, (C r C 6 alkyl)carboxyamido-, HC(O)NH-, H 2 NC(O)-, (d- C 6 alkyl)NHC(O)-, di(Ci-C 6 alkyl)NC(O)-, NC-, hydroxyl, Ci-C 6 alkoxy-, Ci-C 6 alkyl-, HO 2 C- , (Ci-C 6 alkoxy)carbonyl-, (Ci-C 6 alkyl)C(O)-, C 6 -Ci 4 aryl-, C r C 9 heteroaryl-
  • Heteroatom refers to a sulfur, nitrogen, or oxygen atom.
  • Heterocycle or “heterocyclyl-” refers to 3-10-membered monocyclic, fused bicyclic, and bridged bicyclic groups containing at least one heteroatom selected from oxygen, sulfur and nitrogen.
  • a heterocycle may be saturated or partially saturated.
  • Exemplary d-Cgheterocyclyl- groups include but are not limited to aziridine, oxirane, oxirene, thiirane, pyrroline, pyrrolidine, dihydrofuran, tetrahydrofuran, dihydrothiophene, tetrahydrothiophene, dithiolane, piperidine, 1 ,2,3,6-tetrahydropyridine-1 -yl, tetrahydropyran, pyran, thiane, thiine, piperazine, oxazine, 5,6-dihydro-4H-1 ,3-oxazin-2- yl, 2,5-diazabicyclo[2.2.1]heptane, 2,5-diazabicyclo[2.2.2]octane, 3,6- diazabicyclo[3.1.1]heptane, 3,8-diazabicyclo[3.2.1]octane, 6-oxa-3,8- diaza
  • dheterocyclyl- radicals would include but are not limited to oxaziranyl, diaziridinyl, and diazirinyl
  • C 2 heterocyclyl- radicals include but are not limited to aziridinyl, oxiranyl, and diazetidinyl
  • Cgheterocyclyl- radicals include but are not limited to azecanyl, tetrahydroquinolinyl, and perhydroisoquinolinyl.
  • Heterocyclyl(alkyl)- refers to an alkyl group, as defined above, wherein one or more of the alkyl group's hydrogen atoms have been replaced with a heterocycle group as defined above.
  • Heterocyclyl(Ci-C 6 alkyl)- moieties include 2-pyridylmethyl, 1- piperazinylethyl, 4-morpholinylpropyl, 6-piperazinylhexyl, and the like.
  • a heterocyclyl(alkyl) group can be unsubstituted or substituted with one or more of the following groups: halogen, H 2 N-, (Ci-C6alkyl)amino-, di(Ci-C6alkyl)amino-, (Ci- C 6 alkyl)C(O)N(C r C 3 alkyl)-, (C r C 6 alkyl)carboxyamido-, HC(O)NH-, H 2 NC(O)-, (C r C 6 alkyl)NHC(O)-, di(C r C 6 alkyl)NC(O)-, NC-, hydroxyl, C r C 6 alkoxy-, C r C 6 alkyl-, HO 2 C- , (Ci-C6alkoxy)carbonyl-, (Ci-C6alkyl)C(O)-, 4- to 7-membered monocyclic heterocycle, C 6 -Ci 4 aryl
  • Hydrolalkyl- refers to an alkyl group, as defined above, wherein one or more of the alkyl group's hydrogen atoms have been replaced with hydroxyl groups.
  • C-i-C ⁇ hydroxylalkyl- moieties include, for example, -CH 2 OH, -CH 2 CH 2 OH, - CH 2 CH 2 CH 2 OH, -CH 2 CH(OH)CH 2 OH, -CH 2 CH(OH)CH 3 , -CH(CH 3 )CH 2 OH and higher homologs.
  • leaving group refers an atom or group (charged or uncharged) that becomes detached from an atom in what is considered to be the residual or main part of the substrate in a specified reaction.
  • the leaving group is bromide.
  • the leaving group is trimethylamine.
  • the electrophilic nitration of benzene it is H + .
  • the term has meaning only in relation to a specified reaction. Examples of leaving groups include, for example, carboxylates (i.e.
  • Perfluoroalkyl- refers to alkyl group, defined above, having two or more fluorine atoms. Examples of a Ci-C ⁇ perfluoroalkyl- group include CF 3 , CH 2 CF 3 , CF 2 CF 3 and CH(CF 3 ) 2 .
  • optionally substituted means that at least one hydrogen atom of the optionally substituted group has been substituted with halogen, H 2 N-, (C r C 6 alkyl)amino-, di(Ci-C 6 alkyl)amino-, (d- C 6 alkyl)C(O)N(C r C 3 alkyl)-, (C r C 6 alkyl)carboxyamido-, HC(O)NH-, H 2 NC(O)-, (C r C 6 alkyl)NHC(O)-, di(C r C 6 alkyl)NC(O)-, NC-, hydroxyl, C r C 6 alkoxy-, C r C 6 alkyl-, HO 2 C- , (Ci-C 6 alkoxy)carbonyl-, (CrC 6 alkyl)C(O)-, C 6 -Ci 4 aryl-, C r C 9 heteroaryl
  • a “subject” is a mammal, e.g., a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee, baboon or gorilla.
  • the compounds of the present invention exhibit an mTOR inhibitory activity and, therefore, can be utilized to inhibit abnormal cell growth in which mTOR plays a role.
  • the compounds of the present invention are effective in the treatment of disorders with which abnormal cell growth actions of mTOR are associated, such as restenosis, atherosclerosis, bone disorders, arthritis, diabetic retinopathy, psoriasis, benign prostatic hypertrophy, atherosclerosis, inflammation, angiogenesis, immunological disorders, pancreatitis, kidney disease, cancer, etc.
  • the compounds of the present invention possess excellent cancer cell growth inhibiting effects and are effective in treating cancers, preferably all types of solid cancers and malignant lymphomas, and especially, leukemia, skin cancer, bladder cancer, breast cancer, uterus cancer, ovary cancer, prostate cancer, lung cancer, colon cancer, pancreas cancer, renal cancer, gastric cancer, brain tumor, advanced renal cell carcinoma, acute lymphoblastic leukemia, malignant melanoma, soft-tissue or bone sarcoma, etc.
  • the compounds of the present invention exhibit a PI3 kinase inhibitory activity and, therefore, can be utilized in order to inhibit abnormal cell growth in which PI3 kinases play a role.
  • the compounds of the present invention are effective in the treatment of disorders with which abnormal cell growth actions of PI3 kinases are associated, such as restenosis, atherosclerosis, bone disorders, arthritis, diabetic retinopathy, psoriasis, benign prostatic hypertrophy, atherosclerosis, inflammation, angiogenesis, immunological disorders, pancreatitis, kidney disease, cancer, etc.
  • the compounds of the present invention possess excellent cancer cell growth inhibiting effects and are effective in treating cancers, preferably all types of solid cancers and malignant lymphomas, and especially, leukemia, skin cancer, bladder cancer, breast cancer, uterus cancer, ovary cancer, prostate cancer, lung cancer, colon cancer, pancreas cancer, renal cancer, gastric cancer, brain tumor, advanced renal cell carcinoma, acute lymphoblastic leukemia, malignant melanoma, soft-tissue or bone sarcoma, etc.
  • the pharmacologically active compounds of Formula I will normally be administered as a pharmaceutical composition comprising as the (or an) essential active ingredient at least one such compound in association with a solid or liquid pharmaceutically acceptable carrier and, optionally, with pharmaceutically acceptable adjutants and excipients employing standard and conventional techniques.
  • compositions of this invention include suitable dosage forms for oral, parenteral (including subcutaneous, intramuscular, intradermal and intravenous) bronchial or nasal administration.
  • parenteral including subcutaneous, intramuscular, intradermal and intravenous
  • nasal administration if a solid carrier is used, the preparation may be tableted, placed in a hard gelatin capsule in powder or pellet form, or in the form of a troche or lozenge.
  • the solid carrier may contain conventional excipients such as binding agents, fillers, tableting lubricants, disintegrants, wetting agents and the like.
  • the tablet may, if desired, be film coated by conventional techniques.
  • the preparation may be in the form of a syrup, emulsion, soft gelatin capsule, sterile vehicle for injection, an aqueous or non-aqueous liquid suspension, or may be a dry product for reconstitution with water or other suitable vehicle before use.
  • Liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, wetting agents, non-aqueous vehicle (including edible oils), preservatives, as well as flavoring and/or coloring agents.
  • a vehicle normally will comprise sterile water, at least in large part, although saline solutions, glucose solutions and like may be utilized. Injectable suspensions also may be used, in which case conventional suspending agents may be employed.
  • parenteral dosage forms Conventional preservatives, buffering agents and the like also may be added to the parenteral dosage forms. Particularly useful is the administration of a compound of Formula I directly in parenteral formulations.
  • the pharmaceutical compositions are prepared by conventional techniques appropriate to the desired preparation containing appropriate amounts of the active ingredient, that is, the compound of Formula I according to the invention. See, for example, Remington: The Science and Practice of Pharmacy, 20th Edition. Baltimore, MD: Lippincott Williams & Wilkins, 2000.
  • the dosage of the compounds of Formula I to achieve a therapeutic effect will depend not only on such factors as the age, weight and sex of the patient and mode of administration, but also on the degree of potassium channel activating activity desired and the potency of the particular compound being utilized for the particular disorder of disease concerned.
  • the treatment and dosage of the particular compound may be administered in unit dosage form and that one skilled in the art would adjust the unit dosage form accordingly to reflect the relative level of activity.
  • the decision as to the particular dosage to be employed (and the number of times to be administered per day is within the discretion of the physician, and may be varied by titration of the dosage to the particular circumstances of this invention to produce the desired therapeutic effect.
  • a suitable dose of a compound of Formula I or pharmaceutical composition thereof for a mammal, including man, suffering from, or likely to suffer from any condition as described herein is an amount of active ingredient from about 0.01 mg/kg to 10 mg/kg body weight.
  • the dose may be in the range of 0.1 mg/kg to 1 mg/kg body weight for intravenous administration.
  • the dose may be in the range about 0.1 mg/kg to 5 mg/kg body weight.
  • the active ingredient will preferably be administered in equal doses from one to four times a day. However, usually a small dosage is administered, and the dosage is gradually increased until the optimal dosage for the host under treatment is determined.
  • the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances including the condition to be treated, the choice of compound of be administered, the chosen route of administration, the age, weight, and response of the individual patient, and the severity of the patient's symptoms.
  • the amount of the compound of the present invention or a pharmaceutically acceptable salt thereof that is effective for inhibiting mTOR or PI3K in a subject can optionally be employed to help identify optimal dosage ranges.
  • the precise dose to be employed can also depend on the route of administration, the condition, the seriousness of the condition being treated, as well as various physical factors related to the individual being treated, and can be decided according to the judgment of a health-care practitioner.
  • Equivalent dosages may be administered over various time periods including, but not limited to, about every 2 hours, about every 6 hours, about every 8 hours, about every 12 hours, about every 24 hours, about every 36 hours, about every 48 hours, about every 72 hours, about every week, about every two weeks, about every three weeks, about every month, and about every two months.
  • the number and frequency of dosages corresponding to a completed course of therapy will be determined according to the judgment of a health-care practitioner.
  • the effective dosage amounts described herein refer to total amounts administered; that is, if more than one compound of the present invention or a pharmaceutically acceptable salt thereof is administered, the effective dosage amounts correspond to the total amount administered.
  • the compound of the present invention or a pharmaceutically acceptable salt thereof is administered concurrently with another therapeutic agent.
  • a composition comprising an effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof and an effective amount of another therapeutic agent within the same composition can be administered.
  • Effective amounts of the other therapeutic agents are well known to those skilled in the art. However, it is well within the skilled artisan's purview to determine the other therapeutic agent's optimal effective amount range.
  • the compound of the present invention or a pharmaceutically acceptable salt thereof and the other therapeutic agent can act additively or, in one embodiment, synergistically.
  • the effective amount of the compound of the present invention or a pharmaceutically acceptable salt thereof is less than its effective amount would be where the other therapeutic agent is not administered.
  • the compound of the present invention or a pharmaceutically acceptable salt thereof and the other therapeutic agent act synergistically. Procedures used to synthesize the compounds of the present invention are described in Schemes 1 -7 and are illustrated in the examples. Reasonable variations of the described procedures are intended to be within the scope of the present invention:
  • One of the intermediates of formula 2 utilized for introducing the aryl ureido group was prepared starting from 2-(4-isocyanatophenyl)-4,4,5,5-tetramethyl-1 ,3,2- dioxaborolane of formula 1 as shown in Scheme 1.
  • PG is an amine-protecting group and X is independently a leaving group.
  • amine-protecting groups include BOC, FMOC, Z, formyl, benzoyl, thfluoroacetyl, p-tosyl, aryl- and alkylphosphoryl, phenyl- and benzylsulfonyl, o-nitrophenylsulfenyl, o- nitrophenoxyacetyl, tosyloxyalkyloxy-, cyclopentyloxy-, cyclohexyloxy-, 1 ,1 - dimethylpropyloxy, 2-(p-biphenyl)-2-propyloxy- and benzylthiocarbonyl.
  • leaving groups include iodide, bromide, chloride, fluoride, me
  • 6-methyl-6,7-dihydro-5H-pyrrolo[3,4-d]pyhmidine compounds 22 are made by a reductive amination process.
  • Schemes 1-7 can be adapted to produce the other compounds of Formula I and pharmaceutically acceptable salts of compounds of Formula I according to the present invention.
  • ATP is adenosine triphosphate
  • ⁇ ME is 2-mercaptoethanol
  • BOC is tertiary- butyloxycarbonyl
  • BSA Bovine Serum Albumin
  • CHAPS is (3-[(3- cholamidopropyl)dimethylammonio]-1-propanesulfonic acid
  • DELFIA Dissociation- Enhanced Lanthanide Fluorescent Immunoassay
  • DME is 1 ,2-dimethoxyethane
  • DMF is N,N-dimethylformamide
  • DMSO dimethylsulfoxide
  • DPBS Dulbecco's Phosphate Buffered Saline Formulation.
  • DTT is (2S,3S)-1 ,4-bis-sulfanylbutane-2,3-diol or dithiothreitol
  • EDTA is ethylenediaminetetraacetic acid
  • EGTA is ethylene glycol tetraacetic acid
  • EtOAc is ethyl acetate
  • FLAG-TOR is a FLAG-tagged TOR protein
  • HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
  • HPLC high-pressure liquid chromatography
  • microcrystin LR is a cyclic heptapeptide hepatotoxin produced Microcystis aeruginosa containing the amino acids leucine (L) and arginine (R) in the variable positions
  • MS is mass spectrometry
  • mTOR is Mammalian Target of Rapamycin (a protein)
  • MTS is 3-(4, 5-dimethylthiazol-2-yl
  • RaneyTM nickel is a sponge-metal catalyst produced when a block of nickel-aluminum alloy is treated with concentrated sodium hydroxide.
  • RaneyTM is a registered trademark of W. R. Grace and Company.
  • RT is retention time
  • SDS is dodecyl sulfate (sodium salt)
  • SRB is Sulforhodamine B
  • TAMRA is tetramethyl-6-carboxyrhodamine
  • TFA is thfluoroacetic acid
  • THF is tetrahydrofuran
  • TRIS tris(hydroxymethyl)aminomethane.
  • Step 1 Preparation of 1-pyridin-3-yl-3-[4-(4,4,5,5-tetramethyl- [1 ,3,2]dioxaborolan-2-yl)-phenyl]-urea A mixture of 2-(4-isocyanato-phenyl)-4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolane (1 ,
  • Step 3 Preparation of 1 -[4-(4-morpholin-4-yl-5,6,7,8-tetrahydro[3,4-d]pyhmidyl- 2-yl) phenyl]-3-pyhdin-3-ylurea
  • Example 8 Preparation of 1-methyl-3-[4-(4-morpholin-4-yl-5,6,7,8-tetrahydropyhdo[3,4-d]pyrimidin-2-yl) phenyljurea
  • Step 1 Preparation of 1-methyl-3-[4-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2- yl)-phenyl]-urea
  • Step 2 Preparation of 1 -methyl-3-[4-(4-morpholin-4-yl-5,6,7,8-tetrahydro[3,4- d]pyhmidin-2-yl) phenyl]urea
  • Step 1 Preparation of 2-chloro-4-(3-oxa-8-aza-bicyclo[3.2.1]oct-8-yl)-5,8- dihydro-6H-pyrido[3,4-d]pyrimidine-7-carboxylic acid tert-butyl ester
  • a mixture of 2,4-dichloro-5,8-dihydro-6H-pyrido[3,4-d]pyrimidine-7-carboxylic acid tert-butyl ester (3, 860 mg, 2.68 mmol), 3-oxa-8-aza-bicyclo[3.2.1]octane (384 mg, 3.39 mmol), and triethyl amine (343 mg, 3.39 mmol) in 20 ml.
  • Step 2 Preparation of 1 - ⁇ 4-[4-(3-oxa-8-azabicyclo[3.2.1 ]oct-8-yl)-5,6,7,8- tetrahydro[3,4-d]pyhmidyl-2-yl]phenyl ⁇ -3-pyhdin-3-ylurea
  • the reaction mixture was filtered through a silica gel pad (eluting with 10 % methanol/EtOAc). The filtrate was concentrated to get the crude 4-(3-oxa-8-aza-bicyclo[3.2.1]oct-8-yl)-2-[4-(3-pyridin-3-yl-ureido)-phenyl]- 5,8-dihydro-6H-pyhdo[3,4-d]pyhmidine-7-carboxylic acid tert-butyl ester. Then the crude product was dissolved in 10 mL of methylene chloride and treated with 2 mL of TFA for 1 hour.
  • Step 1 2-Chloro-4-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-5,8-dihydro-6H- pyrido[3,4-d]pyhmidine-7-carboxylic acid tert-butyl ester
  • Step 2 Preparation of 1- ⁇ 4-[4-(8-Oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)-5,6,7,8- tetrahydropyrido[3,4-d]pyrimidin-2-yl]-phenyl ⁇ -3-pyridin-3-yl-urea
  • the title compound was prepared by following the procedure step 2 of Example 9 using 1-pyhdin-3-yl-3-[4-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-phenyl]-urea and 2-chloro-4-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-5,8-dihydro-6H-pyrido[3,4-d]pyrimidine-7- carboxylic acid tert-butyl ester.
  • Step 1 Preparation of (4-dimethylaminopiperidin-1 -yl)-(4-nitrophenyl)methanone Hydrochloride
  • Step 2 Preparation of (4-amino-phenyl)-(4-dimethylamino-piperidin-1-yl)- methanone
  • Step 3 Preparation of 1 -[4-(4-dimethylamino-piperidine-1-carbonyl)-phenyl]-3-[4- (4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-phenyl]-urea
  • 4-amino-phenyl)-(4-dimethylamino-pipehdin-1-yl)-methanone (0.59 g, 2.4 mmol)
  • 2-(4-isocyanato-phenyl)-4,4,5,5-tetramethyl- [1 ,3,2]dioxaborolane (1 m 0.59 g, 2.4 mmol) in 30 mL of tetrahydrofuran was stirred at room temperature for 5 hours.
  • Step 4 Preparation of 1 -(4- ⁇ [4-(dimethylamino)piperidin-1 -yl]carbonyl ⁇ phenyl)-3- [4-(4-morpholin-4-yl- 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)phenyl]urea
  • the title compound was prepared by following the procedure of Example 1 Step
  • Example 30 Preparation of N-tert-butyl-2- ⁇ 4-[(methylcarbamoyl)amino]phenyl ⁇ -4- (8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)- carboxamide
  • Example 31 Preparation of 2- ⁇ 4-[(methylcarbamoyl)amino]phenyl ⁇ -4-(8-oxa-3- azabicyclo[S ⁇ .I]oct-3-yO-N-prop ⁇ -en-i-yl-5,8-dihydropyrido[S ⁇ -d]pyrimidine-
  • Example 4 Preparation of 1 -(4- ⁇ 7-[(2-methoxyphenyl)carbonyl]-4-( ⁇ -oxa-3- azabicyclo[3.2.1]oct-3-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin ⁇ -y ⁇ phenyl)-3- methylurea
  • the following compounds were made using methods described above.
  • Example 49 Preparation of i- ⁇ -P-methyl ⁇ - ⁇ -oxa- ⁇ -azabicycloIS ⁇ .Iloct- ⁇ -yl)- 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]phenyl ⁇ -3-pyridin-4-ylurea
  • Step 1 Preparation of 2-chloro-4-morpholin-4-yl-5,7-dihydro-pyrrolo[3,4- d]pyrimidine-6-carboxylic acid tert-butyl ester
  • 2,4-dichloro-5,7-dihydro-pyrrolo[3,4-d]pyrimidine-6-carboxylic acid tert-butyl ester 330 mg, 1.14mmol
  • morpholine 1 19 mg, 1.37 mmol
  • triethyl amine 167mg, 1 .65 mmol
  • Step 2 Preparation of 1-[4-(4-morpholin-4-yl-6, 7-dihydro-5H-pyrrolo[3,4- d]pyhmidin-2-yl)phenyl]-3- pyhdin-3-ylurea
  • Step 1 Preparation of 2-chloro-4- (8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-5,7- dihydro-pyrrolo[3,4-d]pyrimidine-6-carboxylic acid tert-butyl ester
  • the title compound was prepared by following the procedure of Example 80
  • Step 2 Preparation of 1- ⁇ 4-[4-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-6,7-dihydro-5H- pyrrolo[3,4-d]pyrimidin-2-YL]phenyl ⁇ -3-pyridin-3-ylurea
  • Step 1 Preparation of 2-chloro-4- (3-oxa-8-azabicyclo[3.2.1]oct-8-yl)-5,7- dihydro-pyrrolo[3,4-d]pyrimidine-6-carboxylic acid tert-butyl ester
  • the title compound was prepared by following the procedure of Example 80 Step 1 using 2,4-dichloro-5,7-dihydro-pyrrolo[3,4-d]pyrimidine-6-carboxylic acid tert- butyl ester and 3-oxa-8-aza-bicyclo[3.2.1]octane, heating at 30 0 C overnight.
  • Step 2 Preparation of 1- ⁇ 4-[4-(3-oxa-8-azabicyclo[3.2.1 ]oct-8-yl)-6,7-dihydro-5H- pyrrolo[3,4-d]pyrimidin-2-yl]phenyl ⁇ -3-pyhdin-3-ylurea
  • the reaction buffer was 20 mM HEPES, pH 7.5, 2 mM MgCI 2 , 0.05% CHAPS; and 0.01 % ⁇ ME (added fresh).
  • the GST-GRP was 1 .75 mg/mL or 1.4 mg/mL in 10% glycerol.
  • the Red detector (TAMRA) was 2.5 ⁇ M.
  • PI3K assays Nunc 384-well black polypropylene fluorescent plates were used for PI3K assays. The assay is run by placing 5 ⁇ L of diluted enzyme per well, then 5 ⁇ L of diluted compound (or 9.5 ⁇ L enzyme then 0.5 ⁇ L compound in DMSO) is added and mixed. Then, 10 ⁇ L substrate is added to start the reaction. The samples are incubated 30-60 minutes, then the reaction is stopped by adding 20 ⁇ L stop/detector mix. PI3K is diluted with reaction buffer (e.g., 5 ⁇ L or 7.5 ⁇ L PI3K into 620 ⁇ L reaction buffer), and 5 ⁇ L of diluted enzyme is used per well.
  • reaction buffer e.g., 5 ⁇ L or 7.5 ⁇ L PI3K into 620 ⁇ L reaction buffer
  • reaction buffer or of drug diluted in buffer e.g., 4 ⁇ L/100 so final DMSO is 1 % in reaction
  • the enzyme can be diluted to 1215 ⁇ L. In this case 9.8 ⁇ L is added per well and 0.2 ⁇ L compound is added in DMSO.
  • reaction buffer 955 ⁇ L reaction buffer, 40 ⁇ L PIP2, and 2.5 ⁇ L ATP are mixed. 10 ⁇ L of substrate is added to each well to start the reaction. This results in 20 ⁇ M Pl P2, and 25 ⁇ M ATP per reaction.
  • the stop/detector mix is prepared by mixing 4 ⁇ L Red detector and 1.6 ⁇ L or 2.0 ⁇ L GST-GRP with 1 mL stop buffer, which results in 10 nM probe and 70 nM GST-GRP). 20 ⁇ L of the stop/detector mix is added to each well to stop the reaction. The plates are read after 30-90 minutes keeping the red probe solutions dark. For the zero time point, stop/detector mix is added to the enzyme just before adding substrate.
  • stop/detector mix is added to buffer (no enzyme) and substrate or to just buffer (no substrate).
  • Pooled PI3K preparations had a protein concentration of 0.25 mg/mL.
  • the recommended reaction has 0.06 ⁇ L per 20 ⁇ L (0.015 ⁇ g/20 ⁇ L) or 0.01 125 ⁇ g/15 ⁇ L or 0.75 ⁇ g/mL.
  • Plates are read on machines with filters for TAMRA.
  • the units are mP with no enzyme controls reading app 190-220 mP units.
  • Fully active enzyme reduces fluorescence polarization down to 70-100 mP after 30 minutes.
  • An active compound raises the mP values halfway to control or to 120-150 mP units.
  • Compounds of the invention had IC 50 S against PI3K-alpha ranging from 7 nM to 2,858 nM.
  • kinase reaction was initiated by adding 12.5 ⁇ L kinase assay buffer containing ATP and His6-S6K to give a final reaction volume of 25 ⁇ L containing 800 ng/mL FLAG-TOR, 100 ⁇ M ATP and 1.25 ⁇ M His6- S6K.
  • the reaction plate was incubated for 2 hours (linear at 1 -6 hours) at room temperature with gentle shaking and then terminated by adding 25 ⁇ L Stop buffer (20 mM HEPES (pH 7.4), 20 mM EDTA, 20 mM EGTA).
  • the DELFIA detection of the phosphorylated (Thr-389) His6-S6K was performed at room temperature using a monoclonal anti-P(T389)-p70S6K antibody (1A5, Cell Signaling) labeled with Europium- N1-ITC (Eu) (10.4 Eu per antibody, PerkinElmer).
  • the DELFIA Assay buffer and Enhancement solution were purchased from PerkinElmer.
  • 45 ⁇ L of the terminated kinase reaction mixture was transferred to a MaxiSorp plate (Nunc) containing 55 ⁇ L PBS.
  • the His6-S6K was allowed to attach for 2 hours after which the wells were aspirated and washed once with PBS.
  • the human SMG-1 (hSMG-1 ) kinase assay employs the recombinant hSMG-1 protein prepared from transiently transfected HEK293 cells and a GST-p53 (aa 1-70) fusion substrate protein derived from cellular tumor suppressor gene p53.
  • the routine assay is performed in a 96-well plate format as follows. Enzymes were first diluted in kinase assay buffer (10 mM HEPES, pH 7.4, 50 mM NaCI, 0.2 mM DTT, 50 mM ⁇ - glycerophosphate, 0.5 ⁇ M microcystin LR, 10 mM MnCI 2 ).
  • kinase reaction was initiated by adding 12.5 ⁇ L kinase assay buffer containing ATP and GST-p53 to give a final reaction volume of 25 ⁇ L containing 400-800 ng/mL FLAG-hSMG-1 , 0.5 ⁇ g GST-p53, 10 ⁇ M ATP. The reaction was carried out at room temperature for 1 .0 hour before terminated by addition of 25 ⁇ l stop solution. The assay mixture was then transferred to FluoroNunc Plates with MaxiSorp Surface (Nunc #439454).
  • the plates were incubated at room temperature for 2 hr (4 0 C for overnight) to achieve efficient binding of substrate protein to the plate.
  • the plates were aspirated, washed with PBS.
  • Phospho-substrate proteins were detected by incubating for 1 hour with 125 ng of europium-labeled anti-mouse secondary antibody (PerkinElmer AD2027) and the primary phospho(S15)-p53 monoclonal antibody (Cell Signal #9286) in 100 ⁇ l_ DELFIA assay buffer (PerkinElmer #1244-1 1 1 ). Plates were then washed and incubated for 0.5 hour with 100 ⁇ l of DELFIA enhancement solution (PerkinElmer #1244-105). DELFIA assay results are recorded in a Victor Plate Reader (PerkinElmer). Data obtained were used to calculate enzymatic activity and enzyme inhibition by potential inhibitors.
  • the cell lines used were human prostate lines LNCap and PC3MM2, human breast lines MDA468 and MCF7, human renal line HTB44 (A498), human colon line HCT1 16, and human ovarian line OVCAR3. Cells were plated in 96-well culture plates.
  • the inhibitors were added to cells.
  • viable cell densities were determined by metabolic conversion (by viable cells) of the dye MTS, a well-established cell proliferation assay.
  • the assays were performed using an assay kit purchased from Promega Corp. (Madison, Wl) following the protocol supplied with the kit.
  • the MTS assay results were read in a 96-well plate reader by measuring absorbance at 490 nm. The effect of each treatment was calculated as percent of control growth relative to the vehicle-treated cells grown in the same culture plate.
  • the drug concentration that conferred 50% inhibition of growth was determined as IC50.
  • Compounds of the invention had IC50 activities against LNCap cells ranging from 6 nM to >60 uM.
  • Tables 1 and 2 show the results of the described biological assays.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un composé de formule I : ou un de ses sels pharmaceutiquement acceptables, dans lequel les variables constitutives sont telles que définies dans la description, ainsi que des compositions contenant lesdits composés, et des méthodes permettant de préparer et d'utiliser les composés.
PCT/US2010/031188 2009-04-17 2010-04-15 Composés de 5,6,7,8-tétrahydropyrido[3,4-d]pyrimidine, leur utilisation comme inhibiteurs de la mtor kinase et de la pi3 kinase, et leurs synthèses WO2010120996A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17015409P 2009-04-17 2009-04-17
US61/170,154 2009-04-17

Publications (1)

Publication Number Publication Date
WO2010120996A1 true WO2010120996A1 (fr) 2010-10-21

Family

ID=42321099

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/031188 WO2010120996A1 (fr) 2009-04-17 2010-04-15 Composés de 5,6,7,8-tétrahydropyrido[3,4-d]pyrimidine, leur utilisation comme inhibiteurs de la mtor kinase et de la pi3 kinase, et leurs synthèses

Country Status (1)

Country Link
WO (1) WO2010120996A1 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012136622A1 (fr) 2011-04-04 2012-10-11 Cellzome Limited Dérivés de dihydropyrrolopyrimidine en tant qu'inhibiteurs de la mtor
US9051311B2 (en) 2012-03-09 2015-06-09 Amgen Inc. Sulfamide sodium channel inhibitors
CN105777746A (zh) * 2016-03-30 2016-07-20 河南师范大学 具有抗真菌活性的5,6,7,8-四氢吡啶并[3,4-d]嘧啶衍生物的制备方法
WO2017201161A1 (fr) * 2016-05-18 2017-11-23 Mirati Therapeutics, Inc. Inhibiteurs de kras g12c
CN108456183A (zh) * 2018-03-09 2018-08-28 上海工程技术大学 Gedatolisib的制备方法及中间体
WO2018218197A3 (fr) * 2017-05-26 2018-12-27 Board Of Regents, The University Of Texas System Inhibiteurs de la kinase atr à base de tétrahydropyrido[4,3-d]pyrimidine
US10392376B2 (en) 2017-07-13 2019-08-27 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of ATR kinase
US10647715B2 (en) 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
US10689377B2 (en) 2017-11-15 2020-06-23 Mirati Therapeutics, Inc. KRas G12C inhibitors
US10894052B2 (en) 2018-03-16 2021-01-19 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of ATR kinase
US11453683B1 (en) 2019-08-29 2022-09-27 Mirati Therapeutics, Inc. KRas G12D inhibitors
WO2022261210A1 (fr) * 2021-06-08 2022-12-15 Quanta Therapeutics, Inc. Modulateurs de kras et leurs utilisations
US11548888B2 (en) 2019-01-10 2023-01-10 Mirati Therapeutics, Inc. KRas G12C inhibitors
US11702418B2 (en) 2019-12-20 2023-07-18 Mirati Therapeutics, Inc. SOS1 inhibitors
US11890285B2 (en) 2019-09-24 2024-02-06 Mirati Therapeutics, Inc. Combination therapies
US11912723B2 (en) 2022-02-09 2024-02-27 Quanta Therapeutics, Inc. KRAS modulators and uses thereof
US11932633B2 (en) 2018-05-07 2024-03-19 Mirati Therapeutics, Inc. KRas G12C inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008023159A1 (fr) * 2006-08-24 2008-02-28 Astrazeneca Ab Dérivés de la morpholino pyrimidine utiles dans le traitement de maladies prolifératives
WO2010014939A1 (fr) * 2008-07-31 2010-02-04 Genentech, Inc. Composés de pyrimidine, compositions et procédés d'utilisation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008023159A1 (fr) * 2006-08-24 2008-02-28 Astrazeneca Ab Dérivés de la morpholino pyrimidine utiles dans le traitement de maladies prolifératives
WO2010014939A1 (fr) * 2008-07-31 2010-02-04 Genentech, Inc. Composés de pyrimidine, compositions et procédés d'utilisation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMISTRY OF HETEROCYCLIC COMPOUNDS, vol. 43, no. 10, 2007, pages 1320 - 1324 *
DATABASE BEILSTEIN [online] BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; 2007, XP002592519, Database accession no. 11406701 (BRNs) *
VERHEIJEN ET AL.: "Phosphatidylinositol 3-kinase (PI3K) inhibitors as anticancer drugs", DRUGS OF THE FUTURE, vol. 32, no. 6, 1 June 2007 (2007-06-01), pages 537 - 547, XP002503896, ISSN: 0377-8282, DOI: 10.1358/DOF.2007.03206.1107995 *

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014510122A (ja) * 2011-04-04 2014-04-24 セルゾーム リミテッド ｍＴＯＲ阻害剤としてのジヒドロピロロピリミジン誘導体
WO2012136622A1 (fr) 2011-04-04 2012-10-11 Cellzome Limited Dérivés de dihydropyrrolopyrimidine en tant qu'inhibiteurs de la mtor
US9051311B2 (en) 2012-03-09 2015-06-09 Amgen Inc. Sulfamide sodium channel inhibitors
CN105777746A (zh) * 2016-03-30 2016-07-20 河南师范大学 具有抗真菌活性的5,6,7,8-四氢吡啶并[3,4-d]嘧啶衍生物的制备方法
US10633381B2 (en) 2016-05-18 2020-04-28 Mirati Therapeutics, Inc. KRas G12C inhibitors
WO2017201161A1 (fr) * 2016-05-18 2017-11-23 Mirati Therapeutics, Inc. Inhibiteurs de kras g12c
CN109843856B (zh) * 2016-05-18 2023-05-02 米拉蒂治疗股份有限公司 Kras g12c抑制剂
US10125134B2 (en) 2016-05-18 2018-11-13 Mirati Therapeutics, Inc. KRas G12C inhibitors
US11267812B2 (en) 2016-05-18 2022-03-08 Mirati Therapeutics, Inc. KRAS G12C inhibitors
CN109843856A (zh) * 2016-05-18 2019-06-04 米拉蒂治疗股份有限公司 Kras g12c抑制剂
US10745420B2 (en) 2017-05-26 2020-08-18 Board Of Regents, The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase
WO2018218197A3 (fr) * 2017-05-26 2018-12-27 Board Of Regents, The University Of Texas System Inhibiteurs de la kinase atr à base de tétrahydropyrido[4,3-d]pyrimidine
US10421765B2 (en) 2017-05-26 2019-09-24 Board Of Regents, The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase
US10392376B2 (en) 2017-07-13 2019-08-27 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of ATR kinase
US10800769B2 (en) 2017-07-13 2020-10-13 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of ATR kinase
US11434233B2 (en) 2017-07-13 2022-09-06 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of ATR kinase
US10647715B2 (en) 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
US10689377B2 (en) 2017-11-15 2020-06-23 Mirati Therapeutics, Inc. KRas G12C inhibitors
CN108456183A (zh) * 2018-03-09 2018-08-28 上海工程技术大学 Gedatolisib的制备方法及中间体
US10894052B2 (en) 2018-03-16 2021-01-19 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of ATR kinase
US11932633B2 (en) 2018-05-07 2024-03-19 Mirati Therapeutics, Inc. KRas G12C inhibitors
US11548888B2 (en) 2019-01-10 2023-01-10 Mirati Therapeutics, Inc. KRas G12C inhibitors
US11453683B1 (en) 2019-08-29 2022-09-27 Mirati Therapeutics, Inc. KRas G12D inhibitors
US11964989B2 (en) 2019-08-29 2024-04-23 Mirati Therapeutics, Inc. KRas G12D inhibitors
US11890285B2 (en) 2019-09-24 2024-02-06 Mirati Therapeutics, Inc. Combination therapies
US11702418B2 (en) 2019-12-20 2023-07-18 Mirati Therapeutics, Inc. SOS1 inhibitors
WO2022261210A1 (fr) * 2021-06-08 2022-12-15 Quanta Therapeutics, Inc. Modulateurs de kras et leurs utilisations
US11912723B2 (en) 2022-02-09 2024-02-27 Quanta Therapeutics, Inc. KRAS modulators and uses thereof

Similar Documents

Publication Publication Date Title
WO2010120996A1 (fr) Composés de 5,6,7,8-tétrahydropyrido[3,4-d]pyrimidine, leur utilisation comme inhibiteurs de la mtor kinase et de la pi3 kinase, et leurs synthèses
WO2010120994A2 (fr) Composés d'uréido-aryl-pyrimidine et de carbamoylaryl-morpholino-pyrimidine, leur utilisation comme inhibiteurs de la kinase mtor et de la kinase pi-3, et leur synthèse
US8129371B2 (en) Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors
US20100003250A1 (en) (2-aryl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)morpholine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
WO2010120987A1 (fr) Composés de morpholino-pyrimidine à pont uréidoaryle et carbamoylaryle, à cycles condensés, leur utilisation en tant qu'inhibiteurs de kinase mtor et de kinase pi3, et leurs synthèses
EP2419432B1 (fr) Composés de pyrimidine, leur utilisation comme inhibiteurs de la mtor kinase et de la pi3 kinase et leurs procédés de synthèse
US20090298820A1 (en) 3-substituted-1h-pyrrolo[2,3-b]pyridine and 3-substituted-1h-pyrrolo[3,2-b]pyridine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
US20100015141A1 (en) 4-phenoxy-6-aryl-1h-pyrazolo[3,4-d]pyrimidine and n-aryl-6-aryl-1h-pyrazolo[3,4-d]pyrimidin-4-amine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
US20090227575A1 (en) 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS
WO2009070524A1 (fr) Composés de pyrrolo[3,2-d]pyrimidine et leur utilisation comme inhibiteurs de la pi3 kinase et de la mtor kinase
US20090181963A1 (en) 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
ES2728163T3 (es) Compuestos de triazina como inhibidores de PI3 cinasa y mTOR
US20090192176A1 (en) 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
US20100061982A1 (en) 3-substituted-1h-indole, 3-substituted-1h-pyrrolo[2,3-b]pyridine and 3-substituted-1h-pyrrolo[3,2-b]pyridine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
WO2015038417A1 (fr) Composés permettant de réguler les voies fak et/ou src
US20100068204A1 (en) 4-aryloxyquinolin-2(1h)-ones as mtor kinase and pi3 kinase inhibitors, for use as anti-cancer agents
US20090192147A1 (en) [a]-FUSED INDOLE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
WO2010120991A1 (fr) Composés de 5,6,7,8-tétrahydropyrido[4,3-d]pyrimidine, leur utilisation en tant qu'inhibiteurs de kinase mtor, pi3, et hsmg-1, et leurs synthèses
KR20150023798A (ko) 항말라리아 제제로서의 피리미디논 유도체

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10714793

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10714793

Country of ref document: EP

Kind code of ref document: A1